U.S. Markets close in 4 hrs 23 mins

BHC’s Salix Segment: Xifaxan Drove Its Revenues in Q1

Margaret Patrick
BHC’s Salix Segment: Xifaxan Drove Its Revenues in Q1

Bausch Health Companies: An Attractive Pick after Q1 Results?(Continued from Prior Part)Salix segment performanceIn the first quarter, Bausch Health Companies (BHC) reported revenues of $445 million for its Salix segment—a rise of 5% YoY